Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 1, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2014 Healthcare Conference on May 13 in Las Vegas, NV. Susie Lisa, vice president,...
-
May 1, 2014
Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has launched the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent...
-
Apr 29, 2014Company Exceeds Earnings Per Share Guidance on the Strength of Continued Revenue Growth
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.774 billion during the first quarter ended March 31, 2014. This represents 4 percent operational revenue growth (constant currency...
-
Apr 22, 2014
Boston Scientific Corporation (NYSE: BSX) has conducted the first implant in the clinical trial of the next generation ACUITY™ X4 left-ventricular (LV) pacing leads and RELIANCE™ 4-FRONT...
-
Apr 17, 2014Event Will Be Held in San Francisco, Site of the Heart Rhythm Society 35th Annual Scientific Sessions
Boston Scientific Corporation (NYSE: BSX) will host an investor event on May 8, 2014 to provide an update on company Cardiac Rhythm Management and Electrophysiology initiatives as well as...
-
Apr 15, 2014
Boston Scientific Corporation (NYSE: BSX) has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. The newly approved...
-
Apr 10, 2014Study to Evaluate Clinical Outcomes and Economic Value of the Vercise™ Deep Brain Stimulation (DBS) System
Boston Scientific Corporation (NYSE: BSX) has enrolled the first patient in a new registry to evaluate clinical outcomes and the economic value of the Vercise™ Deep Brain Stimulation (DBS)...
-
Apr 7, 2014The first implant of the S-ICD System performed in Hong Kong
Boston Scientific Corporation (NYSE: BSX) has expanded the launch of its S-ICD System into parts of Asia. The first implant of the S-ICD System in Asia was performed in Hong Kong by Prof. Hung Fat...
-
Apr 7, 2014Innovative handle design enables physician preferences for precision, comfort and control when acquiring tissue samples during diagnostic procedures
Boston Scientific Corporation (NYSE: BSX) has received clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe for the Expect™ Slimline (SL) Needle, which is...
-
Apr 1, 2014These and Other Studies Reinforce Global Commitment to the Development of Innovative Therapies to Improve Care for Patients with Cardiovascular Disease
Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation...
-
Apr 1, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2014 on...
-
Apr 1, 2014Interim results of the EFFORTLESS registry published in the European Heart Journal
Real-world data on the Boston Scientific Corporation (NYSE:BSX) S-ICD System (Subcutaneous Implantable Defibrillator) are highlighted online this week...
-
Mar 30, 2014MADIT-CRT Long-Term Follow-up Results Presented at the American College of Cardiology and Published in the New England Journal of Medicine
In the longest follow-up to date of cardiac resynchronization therapy (CRT) for mild heart failure patients, Boston Scientific Corporation's (NYSE:...
-
Mar 27, 2014Includes Late Breaking Clinical Trial Assessing Use of the Boston Scientific CRT-D Therapyin Patients with Mild Heart Failure
At the 63rd Annual Scientific Session of the American College of Cardiology (ACC), March 29 – 31 in Washington, D.C., Boston Scientific Corporation...
-
Mar 19, 2014
Boston Scientific has received a Shingo award from the Shingo Institute, part of the Jon M. Huntsman School of Business at Utah State University, in...
-
Mar 14, 2014First implant took place in France, at the Nouvelles Cliniques Nantaises in Nantes
Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval and European market launch of the INGEVITY™ family of magnetic resonance...
-
Mar 12, 2014Newest Bare Metal Stent Technology Features Advanced Architecture and Provides Physicians with Enhanced Treatment Option for Patients
Continuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the REBEL™ Platinum...
-
Mar 3, 2014
The Board of Directors of Boston Scientific Corporation (NYSE: BSX) has elected Edward J. Ludwig as a Director. The appointment of Mr. Ludwig will...
-
Feb 28, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Barclays Global Healthcare Conference on March 11 in Miami Beach. Dan...
-
Feb 26, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen and Company 34th Annual Healthcare Conference on March 4 in Boston....
-
Feb 24, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in two conferences, the 2014 Citi Global Healthcare Conference and the RBC...
-
Feb 14, 2014Fully Covered Metal Stent Provides New Treatment Option for Patients with Refractory Benign Esophageal Strictures
Boston Scientific Corporation (NYSE: BSX) has received CE Mark in Europe for its WallFlex™ Esophageal Fully Covered Stent to treat refractory benign...
-
Feb 5, 2014System Provides Physicians New Option for Treating Complete Blockages in the Major Arteries of the Leg
Boston Scientific (NYSE: BSX) has announced the U.S. launch and first use of the OffRoad™ Re-Entry Catheter System, an important addition to the...
-
Feb 4, 2014Fourth Quarter Marks Third Consecutive Quarter of Improved Performance
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.838 billion during the fourth quarter ended December 31, 2013. This represents 5...
-
Feb 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Leerink Swann Global Healthcare Conference on Wednesday, February...
-
Jan 21, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and full year ended...
-
Jan 6, 2014Boston Scientific Names Craig Thompson, M.D. As New Chief Medical Officer, Interventional Cardiology
Boston Scientific Corporation (NYSE: BSX) announces the appointment of Craig Thompson, M.D., as senior vice president and chief medical officer,...
-
Jan 2, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 32nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014 in
-
Dec 17, 2013
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4,...
-
Dec 16, 2013
The Board of Directors of Boston Scientific Corporation (NYSE: BSX) has elected David Roux as a Director. The appointment of Mr. Roux will fill a...
-
Dec 11, 2013
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority,...
-
Dec 6, 2013New Retrospective Data Presented at NANS 2013 Show Highly Significant Reduction in Pain and High Trial Therapy Success Rate of Precision Spectra in the Treatment of Chronic Pain
New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate...
-
Dec 6, 2013
Boston Scientific Corporation (NYSE: BSX) and The Medicines Company (NASDAQ: MDCO) announce a co-promotion agreement for the...
-
Nov 25, 2013Advanced Stent Technology to Launch Immediately in the United States
Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug...
-
Nov 22, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 25th Annual Piper Jaffray Healthcare Conference on December 3 in New...
-
Nov 21, 2013
Boston Scientific Corporation (NYSE: BSX) announces the appointment of Susan (Susie) Vissers Lisa as vice president, Investor Relations, effective...
-
Nov 19, 2013Boston Scientific Receives FDA Clearance And CE Mark Approval For Direxion™ Torqueable MicrocatheterProprietary Shaft Design Enables Better Control In Hard-To-Navigate Vessels
Further bolstering its market-leading portfolio of peripheral embolization technologies, Boston Scientific Corporation (NYSE: BSX) has received U.S....
-
Nov 19, 2013First System To Selectively Stimulate Targeted Areas Of The Brain To Manage Symptoms of Debilitating Disease
The Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System has received CE Mark approval for the treatment...
-
Nov 15, 2013Patients In Germany Receive New Transcatheter Aortic Valve Implantation Devices Specially Designed For Total Control And Accurate Deployment
Marking a major step forward in the evolution of Transcatheter Aortic Valve Implantation (TAVI) technology, the first two commercial implants of the...
-
Nov 6, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Credit Suisse Healthcare Conference on November 12 in Scottsdale,...
-
Nov 1, 2013
Boston Scientific Corporation (NYSE:BSX) today closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business of...
-
Oct 31, 2013New Data Announced At TCT 2013 Demonstrate Successful Deployment In All 120 Patients With No Severe Paravalvular Regurgitation At 30 Days
The Boston Scientific Corporation (NYSE: BSX) Lotus™ Valve System met a key performance measure in the treatment of symptomatic patients with...
-
Oct 31, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Credit Suisse Healthcare Conference on November 12 in Scottsdale,...
-
Oct 28, 2013REDUCE-HTN Data Presented Today at TCT Demonstrate Excellent Safety Profile
Patients treated with the Boston Scientific (NYSE: BSX) Vessix™ Renal Denervation System experienced a significant and sustained reduction in blood...
-
Oct 28, 2013
Boston Scientific Corporation (NYSE: BSX) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful...
-
Oct 28, 2013Transcatheter Aortic Valve Replacement (TAVR) Device Offers Precise Positioning and Placement, Offering Physicians Unprecedented Control
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Lotus™ Valve System, the company's advanced transcatheter aortic valve...
-
Oct 24, 2013Jeffrey Capello to Transition Out of CFO Role at Year-End
Boston Scientific Corporation (NYSE: BSX) has initiated a transition plan for its new chief financial officer. Noting a desire to pursue opportunities...
-
Oct 24, 2013
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.735 billion and adjusted earnings per share of $0.17 for the third quarter ended...
-
Oct 23, 2013Revolutionary procedure clinically proven to provide long term reduction of asthma exacerbations
Boston Scientific Corporation (NYSE: BSX) has received China Food and Drug Administration approval for the Alair® Bronchial Thermoplasty System, an...
-
Oct 23, 2013Award Recognizes Innovative S-ICD® System, the World's First and Only Subcutaneous Implantable Defibrillator
The Boston Scientific Corporation (NYSE: BSX) S-ICD® System has received the Prix Galien USA 2013 Award for Best Medical Technology. The S-ICD...